The Patent Finder

Follistatin-Related Fusion Proteins

Acceleron Pharma Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 5 of these applications claim priority to application 62/007,908, filed Jun 4, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 10,010,498Methods for Treatment of Amyotrophic Lateral Sclerosis with Follistatin Fusion Proteins
In force
 · High confidence
UsedRemaining
Acceleron Pharma Inc.In forceHigh confidence
US 10,023,621Follistatin-Related Fusion Proteins
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 11,497,792Methods for Treatment of Duchenne Muscular Dystrophy with Follistatin Polypeptides
In force
 · Medium confidence
Acceleron Pharma Inc.In forceMedium confidence
US 10,765,626Methods for Treatment of Charcot-Marie-Tooth Disease with Follistatin Polypeptides
In force
 · Medium confidence
Acceleron Pharma Inc.In forceMedium confidence
US 10,954,279Methods and Compositions for Treatment of Disorders with Follistatin Polypeptides
In force
 · Medium confidence
Acceleron Pharma Inc.In forceMedium confidence
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited